AbbVie to Fund Mitokinin's Parkinson Research with Option to Buy

AbbVie to Fund Mitokinin's Parkinson Research with Option to Buy

Source: 
BioSpace
snippet: 

AbbVie bought an exclusive right to acquire San Francisco-based Mitokinin after the company completes its Investigational New Drug (IND)-enabling studies on its lead program, PINK1, for Parkinson’s disease.